Un sitio oficial del Gobierno de los Estados Unidos
Así es como usted puede verificarlo
El .gov significa que es oficial.
Los sitios web del gobierno federal siempre usan un dominio .gov o .mil. Antes de compartir información confidencial en línea, asegúrese de estar en un sitio .gov o .mil.
Este sitio es seguro.
El https:// medios todos los datos transmitidos son cifrados - en otras palabras, cualquier información o el historial de navegación que proporcione se transmite de forma segura.
Legal Library: Cases and Proceedings
Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Thermo Fisher Scientific Inc. agreed to sell assets to GE Healthcare to settle Federal Trade Commission charges that its proposed $13.6 billion acquisition of Life Technologies Corporation (Life) would likely substantially lessen competition.The FTC complaint alleged that the deal, as it was originally proposed, would have eliminated close competition between Thermo Fisher and Life and substantially increased concentration in the markets for short/small interfering ribonucleic acid (siRNA) reagents, cell culture media, and cell culture sera, enabling the combined firm to raise prices and reduce quality for consumers. The proposed order settling the FTC’s charges requires Thermo Fisher to divest its gene modulation business Dharmacon, which contains the siRNA reagents business, as well as its cell culture media and sera business including the HyClone brand to GE Healthcare, along with all intellectual property and know-how necessary to operate each of the divested businesses.
Media research company Nielsen Holdings N.V. settled charges that its acquisition of Arbitron Inc. may substantially lessen competition for national syndicated cross-platform audience measurement services. Nielsen and Arbitron are the best-positioned firms to develop (or partner with others to develop) a national syndicated cross-platform audience measurement service because of their existing audience measurement panels and proven audience measurement technology assets. To settle the charges, the Commission required the divestiture of assets related to Arbitron’s cross-platform audience measurement business, including data from its representative panel, to a Commission-approved buyer.
Pharmaceutical companies Endo Health Sciences Inc. (Endo) and Boca Life Science Holdings, LLC and Boca Pharmacal, LLC (Boca) agreed to a settlement resolving FTC charges that Endo’s acquisition of Boca would be anticompetitive. Under the settlement, the companies will relinquish their rights to market and distribute four generic multivitamin fluoride drops for children, and will sell three other generic drugs in development.The proposed settlement preserves competition in the pharmaceutical markets for four prescription generic multivitamin drop products given to children in the United States who do not have access to fluoridated water. In addition, the FTC’s settlement preserves future competition for three generic drugs where the proposed acquisition would eliminate one likely future entrant from a very limited pool of future entrants.
